

Neuro aktuell

Ausgabe 1-2020

Literatur

Schwerpunkt: Tuberöse Sklerose

Titel: Tuberöse-Sklerose-Komplex: Praktische Tipps (S. 7–10)

Autoren: G. Koukou, S. Lehmann, J.-U. Schlump

Literatur:

1. Northrup H & Kruger D. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol* 2013; 49(4): 243–254
2. Qin W et al. Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. *Hum Genet* 2010; 127: 573–582
3. Randle SC. Tuberous Sclerosis Complex: A Review. *Pediatr Ann* 2017; 46(4): e166–e171
4. Hertzberg C & Martin P. Der Tuberöse Sklerose Komplex Bremen: UNI MED; 2013
5. Gesellschaft für Neuropädiatrie: Therapie der Blitz-Nick Salaam Epilepsie (West Syndrom). (<https://www.awmf.org/leitlinien/detail/II/022-022.html>)
6. Zhang B et al. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. *PLoS One* 2013; 8(2): e57445
7. O’Callaghan FJ et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. *Lancet Neurol* 2017; 16(1): 33–42
8. Tao Y et al. The Vigabatrin Induced Retinal Toxicity is Associated with Photopic Exposure and Taurine Deficiency: An In Vivo Study. *Cell Physiol Biochem* 2016; 40(5): 831–846
9. Saxena A & Sampson JR. Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments. *Semin Neurol* 2015; 35(3): 269–276. doi: 10.1055/s-0035-1552616
10. Ostrowsky-Coste K et al. Resective surgery in tuberous Sclerosis complex, from Penfield to 2018: A critical review. *Rev Neurol (Paris)* 2019; 175(3): 163–182
11. Curatolo P et al. Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. *Eur J Paediatr Neurol* 2018; 22(5): 738–748
12. Dragoumi P et al. Diagnosis of Tuberous Sclerosis Complex in the Fetus, *European Journal of Paediatric Neurology* (2018), doi: 10.1016/j.ejpn.2018.08.005
13. Darcy A. Krueger MD PhDa, Hope Northrup MDdb, on behalf of the International Tuberous Sclerosis Complex Consensus Group Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol* 2013; 49: 255–265

14. Davis PE et al. Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants. *Pediatrics* 2017; 140(6): e20164040. doi:10.1542/peds.2016-4040
15. Kurlemann G & Knuf M. Tuberöse-Sklerose-Komplex. *Kinderärztliche Praxis* 2019; 90: 82–86
16. Dhulipudi B et al. Symptomatic improvement using everolimus in infants with cardiac rhabdomyoma. *Ann Pediatr Cardiol* 2019; 12(1): 45–48
17. de Vries PJ et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. *Pediatr Neurol* 2015; 52(1): 25–35
18. de Vries PJ et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. *Orphanet J Rare Dis.* 2018; 13(1): 157. doi: 10.1186/s13023-018-0901-8
19. Ebrahimi-Fakhari D et al. Dermatological manifestations of tuberous sclerosis complex (TSC). *J Dtsch Dermatol Ges* 2017; 15(7): 695–700
20. Taïeb A et al. Special Considerations in Children with Vitiligo. *Dermatol Clin* 2017; 35(2): 229–233. doi: 10.1016/j.det.2016.11.011
21. Roach ES. Applying the lessons of tuberous sclerosis: The 2015 Hower Award Lecture. *Pediatr Neurol* 2016; 63: 6–22
22. Saffari A et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study. *Orphanet J Rare Dis* 2019; 14(1): 96. doi:10.1186/s13023-019-1077-6
23. Bühren R et al. Tuberöse Sklerose – Interdisziplinäre Herausforderungen der Transition *Monatsschrift Kinderheilkunde* 2013; 161(9)

Schwerpunkt: Parkinson

Titel: Die Pathogenese und Therapie des Morbus Parkinson 2020 (S. 12–19)

Autor: H. Przuntek

Literatur:

1. Przuntek H. Therapie der Parkinson'schen Krankheit. *Med. Klin* 1979; 74: 1077–1083
2. Przuntek H. Morbus Parkinson Früherkennung und Differentialdiagnose. *Med Klin* 1984; 79(1): 2–8
3. Przuntek H. et al. The protective effect of 1-tert.butyl-4,4-diphenylpiperidine against the nigrosriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Life Sciences* 1985; 37: 1195–1200

4. Przuntek H. Riederer P. Early diagnosis and preventive therapy in Parkinson's disease Springer Verlag Wien 1989; 1–442
5. Przuntek H. Early diagnosis in Parkinson's Disease Pathobiology and Clinics of Basal Ganglia Disorders. J Neural Transm 1992; 38: 105-114
6. Przuntek H. et al. Instrumental methods and scoring in extrapyramidal disorders. Springer Verlag 1995; 1–268
7. Przuntek H. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long- term results of the PRADO study. J Neural Transm 1998; 103(6): 717–7
8. Przuntek et al. Seledo: a 5-year long term trial on the effect of selegilin in early parkinsonian patients treated with levodopa. Eur J Neurol 1999; 6(2): 141–15
9. Przuntek H et al. Diagnostic staging of Parkinson's Disease: Conceptual aspects. J Neurol Transm 2004; 111(2): 201–216
10. Müller T et al. Tolcapone increases maximum concentration of levodopa. J Neural Transm 2000; 107(1): 113–119
11. Ferreira JJ et al. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol 2019; 26(7): 953–960. doi:10.1111/ene.13914
12. Braak H et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110(5): 517–536
13. Forsyth CB et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011; 6(12): e28032
14. Shannon KM et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012; 27(6):716–719
15. Schwiertz AJ et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease. Parkinsonism Relat Disord 2018; 50: 104–107

16. Devos D et al. Colonic inflammation in Parkinson's disease. *Neurobiol Dis* 2013; 50: 42–48
17. Mulak A et al. Fecal Calprotectin as a Marker of the Gut Immune System Activation Is Elevated in Parkinson's Disease. *Front Neurosci* 2019; 13: 992
18. Houser MC et al. Stool Immune Profiles Evidence Gastrointestinal Inflammation in Parkinson's Disease. *Mov Disord* 2018; 33(5): 793–804
19. Lin JC et al. Association Between Parkinson's Disease and Inflammatory Bowel Disease: a Nationwide Taiwanese Retrospective Cohort Study. *Inflamm Bowel Dis* 2016; 22: 1049–1055
20. Houser MC & Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? *NPJ Parkinsons Dis* 2017; 3: 3
21. Goffredo M et al. Role of Gut Microbiota and Short Chain Fatty Acids in Modulating Energy Harvest and Fat Partitioning in Youth. *J Clin Endocrinol Metab* 2016; 101: 4367–4376
23. Wong MW et al. Impact of vegan diets on gut microbiota: An update on the clinical implications. *Ci Ji Yi Xue Za Zhi* 2018; 30: 200–203
24. Haghikia A et al. Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. *Immunity* 2015; 43: 817–829
25. Cersosimo MG et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. *J Neurol* 203; 260(5): 1332–1338
26. Sampson TR. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. *Cell* 2016; 167: 1469–1480. e1412
27. Andoh A. Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. *JPEN J Parenter Enteral Nutr* 1999; 23(5): 70–73
28. Drago LM et al. Persisting changes of intestinal microbiota after bowel lavage and colonoscopy. *Eur J Gastroenterol Hepatol* 2016; 28(5): 532–537

29. Canani RB et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol* 2011; 17(12): 1519–1528
30. Unger MM. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. *Parkinsonism Relat Disord* 2016; 32: 66–72
31. van Kessel SP. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. *Nat Commun* 2019; 10: 310
32. Vital M. Colonic Butyrate-Producing Communities in Humans: an Overview Using Omics Data. *mSystems* 2017; 2
33. Kim SJ et al. Dietary fat intake and age modulate the composition of the gut microbiota and colonic inflammation in C57BL/6J mice. *BMC Microbiol* 2019; 19: 193
34. Gerhardt S & Mohajeri MH. Changes of Colonic Bacterial Composition in Parkinson's Disease and Other Neurodegenerative Diseases. *Nutrients* 2018; 10
35. Hegelmaier T et al. The interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson's disease. *Cells* in revision 2020
36. Przuntek H & Hegelmaier T. The longterm healing process of Ayurveda therapy in a patient with Parkinson's disease. *New England Journal of Medicine* 2020; Zur Publikation eingereicht
37. Charaka 100–200 p. Ch. Charaka Samhitas beschrieben in Srikanta Sence 2005; 2 Bände

Zusatzthema: ADHS

Titel: ADHS im Erwachsenenalter und Borderline-Persönlichkeitsstörung (S. 28–33)

Autoren: R. Murphy, M. Armbrust

Literatur:

1. Hoffmann H. *Der Struwwelpeter*. Frankfurt. Insel. 1847

2. Merikangas KR, He JP, Burstein M et al. Lifetime prevalence of mental disorders in U.S. adolescents: Results from the National Comorbidity Survey Replication-Adolescent supplement (NCS-A). *Journal of the American Academy of Child & Adolescent Psychiatry* 2010; 49 (10): 980–9
3. Kessler RC, Adler L, Barkley RA et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. *American Journal of Psychiatry* 2006; 163 (4): 716–23
4. Biederman J, Faraone SV, Monuteaux MC. Gender effects on ADHD in adults, revisited. *Biological Psychiatry* 2004; 55 (7): 692–700
5. Rösler M, Retz W, Retz-Junginger P et al. ADHS-Diagnose bei Erwachsenen. *Der Nervenarzt* 2008; 79(3): 320–7
6. Tebartz van Elst L. Autismus und ADHS. Kohlhammer W GmbH. Stuttgart. 1. Auflage 2016
7. Krause J, Krause K-H ADHS im Erwachsenenalter: Symptome, Differentialdiagnose, Therapie. Schattauer Verlag. Stuttgart. 4. Auflage. 2013
8. Waldmann I, Rhee S. Behavioral and molecular genetic studies. In: Sandberg S (ed.). *Hyperactivity and attention disorders of childhood*. Wiley. New York. 2002
9. Jensen CM, Steinhausen HC. Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. *Atten Defic Hyperact Disord* 2015; 7(1): 27–38
10. Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. *CNS Spectr* 2008; 13(11): 977–84
11. Jacob CP, Gross-Lesch S, Reichert S et al. Sex- and Subtype-Related Differences of Personality Disorders (Axis II) and Personality Traits in Persistent ADHD. *J Atten Disord* 2016; 20(12): 1056–65
12. Asherson P, Young AH, Eich-Höchli D et al. Differential diagnosis, comorbidity, and treatment of attention-deficit/ hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. *Curr Med Res Opin* 2014; 30(8): 1657–72

13. Guilé JM, Biossel L, Alaux-Cantin S et al. Borderline personality disorder in adolescents: prevalence, diagnosis, and treatment strategies. *Adolesc Health Med Ther* 2018; 23(9): 199–210
14. Miller T, Nigg J, Faraone S. Axis I and II comorbidity in adults with ADHD. *Journal of Abnormal Psychology* 2007; 116(3): 519–28
15. S3-Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter“ (2018), AWMF-Registernr. 028–045
16. Matthies SD, Philipsen A. Common ground in attention-deficit/hyperactivity disorder (ADHD) and Borderline personality disorder (BPD) – review of recent findings. *Borderline Personality Disorder and Emotion Dysregulation* 2014; 1: 3
17. Philipsen A. Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. *Eur Arch Psychiatry Clin Neurosci* 2006; 256 Suppl 1: 42–6
18. Vidal-Estrada R, Bosch-Munso R, Noqueira-Morais M et al. Psychological treatment of attention deficit hyperactivity disorder in adults: a systematic review. *Actas Esp Psiquiatr* 2012; 40(3): 147–54